PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-37

  1. 1,748 Posts.
    lightbulb Created with Sketch. 1895
    Hi Zenox, noting your scepticism about whether these results imply impact on fibrosis, do you happen to know what the standard treatment is for acute inflammatory response - and how iPPS compares? I suppose what i'm ultimately trying to divine is whether this would be material on it's own and could displace current treatments?


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.